Review: Risk for cardiovascular events is increased with rofecoxib, diclofenac, and indomethacin, but not celecoxib

Bradley, Colin P.
January 2007
ACP Journal Club;Jan/Feb2007, Vol. 146 Issue 1, p24
Academic Journal
The article offers information on a research study regarding risk factors that lead to cardiovascular (CV) events in patients using cyclo-oxygenase 2 inhibitors and nonsteroidal anti-inflammatory drugs. The study was conducted by researcher P. McGettigan, and published in the "Journal of the American Medical Association." It was found that CV events are increased with rofecoxib, diclofenac and indomethacin.


Related Articles

  • Cardiovascular Risk with Non-Steroidal Anti-Inflammatory Drugs: Systematic Review of Population-Based Controlled Observational Studies. McGettigan, Patricia; Henry, David // PLoS Medicine;Sep2011, Vol. 8 Issue 9, p1 

    Background: Randomised trials have highlighted the cardiovascular risks of non-steroidal anti-inflammatory drugs (NSAIDs) in high doses and sometimes atypical settings. Here, we provide estimates of the comparative risks with individual NSAIDs at typical doses in community settings. Methods and...

  • COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk. Graham, David J. // JAMA: Journal of the American Medical Association;10/4/2006, Vol. 296 Issue 13, p1653 

    The article discusses how doctors and the U. S. Food and Drug Administration were led to approve nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors in spite of evidence that they caused cardiovascular side-effects. Soon after its release, studies showed that rofecoxib reduced...

  • Effect of Rofecoxib on Pain Caused by Osteoid Osteoma. Carpintero-Benitez, Pedro; Aguirre, Maria Angeles; Serrano, Jose Antonio; Lluch, Mercedes // Orthopedics;Nov2004, Vol. 27 Issue 11, p1188 

    In a prospective study, nine patients with osteoid osteoma were treated with a selective cyclooxygenase-2 inhibitor (rofecoxib). Patient pain perception with no treatment, with conventional nonsteroidal anti-inflammatory drug (NSAID) treatment, and with rofecoxib therapy was compared using a...

  • Balancing the cyclooxygenase portfolio. Armstrong, Paul W. // CMAJ: Canadian Medical Association Journal;5/23/2006, Vol. 174 Issue 11, p1581 

    Presents an opinion on issues associated with the introduction and withdrawal from general use of rofecoxib (Vioxx), a selective cyclooxygenase (COX)-2 inhibitor. Overview its mechanism of action; Risk associated with rofecoxib in elderly patients; Recommendation given by an expert advisory...

  • Progress in COX-2 Inhibitors: A Journey So Far. Chakraborti, Asit K.; Garg, Sanjeev K.; Kumar, Raj; Motiwala, Hashim F.; Jadhavar, Pradeep S. // Current Medicinal Chemistry;May2010, Vol. 17 Issue 15, p1563 

    The non-steroidal anti-inflammatory drugs (NSAIDs) are diverse group of compounds used for the treatment of inflammation, since the introduction of acetylsalicylic acid in 1899. Traditional (first generation) NSAIDs exert anti-inflammatory, analgesic, and antipyretic effects through the blockade...

  • NSAID Use in Individuals alt Risk of Renal Adverse Events. Roughead, Elizabeth E.; Ramsay, Emmae; Pratt, Nicole; Gilbert, Andrew L. // Drug Safety;2008, Vol. 31 Issue 11, p997 

    Background: Cyclo-oxygenase (COX)-2 inhibitors were introduced to world markets with claims of improved gastrointestinal safety compared with traditional NSAIDs. Randomized clinical trials had demonstrated fewer adverse gastrointestinal events with COX-2 inhibitors, but no difference with other...

  • Adverse Reaction Research.  // Reactions Weekly;12/6/2008, Issue 1231, p3 

    A conference paper about COX-2 inhibitors in subjects for whom blood pressure (BP) data were available is presented. It states that compared with placebo, the risk of developing new hypertension was increased with COX-2 inhibitors and this was driven largely by the increased risk associated with...

  • Is rofecoxib safer than naproxen? Adelman, Alan // Journal of Family Practice;Mar2001, Vol. 50 Issue 3, p204 

    The article examines whether taking rofecoxib will lead to lesser gastrointestinal events than naproxen, a nonselective nonsteroidal anti-inflammatory drugs (NSAID). There are documents proving that older nonselective NSAID lead to adverse gastrointestinal effects. The events are caused by drug...

  • Caution urged over NSAID findings. Topham-Kindley, Liane // New Zealand Doctor;6/29/2005, p4 

    Focuses on the results of studies on the cardiovascular risks associated with nonsteroidal anti-inflammatory drugs. Comparison of the risk factors of cyclooxygenase-2 (cox-2) inhibitor refecoxib and NSAID diclofenac and ibuprofen according to a British study; Effect of high doses of cox-2...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics